14,631 Shares in Incyte Co. (NASDAQ:INCY) Acquired by Integrated Advisors Network LLC

Integrated Advisors Network LLC bought a new position in shares of Incyte Co. (NASDAQ:INCY - Free Report) during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund bought 14,631 shares of the biopharmaceutical company's stock, valued at approximately $967,000.

A number of other large investors have also modified their holdings of INCY. Vanguard Group Inc. increased its holdings in shares of Incyte by 0.9% in the 1st quarter. Vanguard Group Inc. now owns 22,715,821 shares of the biopharmaceutical company's stock valued at $1,294,120,000 after purchasing an additional 196,440 shares in the last quarter. Acadian Asset Management LLC increased its holdings in Incyte by 28.0% in the second quarter. Acadian Asset Management LLC now owns 3,560,989 shares of the biopharmaceutical company's stock valued at $215,833,000 after buying an additional 779,243 shares in the last quarter. LSV Asset Management lifted its position in shares of Incyte by 0.5% during the 2nd quarter. LSV Asset Management now owns 2,769,892 shares of the biopharmaceutical company's stock valued at $167,911,000 after acquiring an additional 15,115 shares during the period. Pacer Advisors Inc. boosted its stake in shares of Incyte by 17,460.4% during the 2nd quarter. Pacer Advisors Inc. now owns 2,692,182 shares of the biopharmaceutical company's stock worth $163,200,000 after acquiring an additional 2,676,851 shares in the last quarter. Finally, AQR Capital Management LLC grew its holdings in shares of Incyte by 70.5% in the 2nd quarter. AQR Capital Management LLC now owns 2,661,758 shares of the biopharmaceutical company's stock worth $159,905,000 after acquiring an additional 1,101,041 shares during the period. 96.97% of the stock is owned by hedge funds and other institutional investors.

Incyte Trading Up 0.3 %

Shares of NASDAQ:INCY traded up $0.19 during midday trading on Thursday, reaching $74.12. The company's stock had a trading volume of 2,024,260 shares, compared to its average volume of 2,335,401. The firm has a market cap of $14.28 billion, a price-to-earnings ratio of 22.46, a price-to-earnings-growth ratio of 5.31 and a beta of 0.73. The business has a 50 day moving average price of $65.80 and a 200 day moving average price of $61.68. Incyte Co. has a 1 year low of $50.27 and a 1 year high of $74.68. The company has a quick ratio of 1.84, a current ratio of 1.92 and a debt-to-equity ratio of 0.01.

Incyte (NASDAQ:INCY - Get Free Report) last posted its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported ($1.82) EPS for the quarter, missing the consensus estimate of $0.78 by ($2.60). Incyte had a net margin of 2.52% and a return on equity of 0.75%. The business had revenue of $1.04 billion during the quarter, compared to analysts' expectations of $1.01 billion. During the same quarter last year, the firm earned $0.77 EPS. The firm's quarterly revenue was up 9.3% compared to the same quarter last year. Research analysts forecast that Incyte Co. will post 0.66 EPS for the current year.

Insider Buying and Selling

In other Incyte news, EVP Jonathan Elliott Dickinson sold 8,450 shares of Incyte stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $62.36, for a total value of $526,942.00. Following the transaction, the executive vice president now owns 36,390 shares in the company, valued at $2,269,280.40. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, insider Thomas Tray sold 572 shares of the stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $62.94, for a total transaction of $36,001.68. Following the completion of the sale, the insider now owns 24,825 shares of the company's stock, valued at approximately $1,562,485.50. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Jonathan Elliott Dickinson sold 8,450 shares of Incyte stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $62.36, for a total transaction of $526,942.00. Following the transaction, the executive vice president now directly owns 36,390 shares in the company, valued at approximately $2,269,280.40. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 17.50% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on INCY shares. William Blair reaffirmed an "outperform" rating on shares of Incyte in a report on Monday, September 9th. Truist Financial reaffirmed a "hold" rating and set a $74.00 price target (down previously from $83.00) on shares of Incyte in a research note on Wednesday, September 18th. Cantor Fitzgerald reiterated a "neutral" rating on shares of Incyte in a research report on Monday, September 16th. JMP Securities restated a "market perform" rating on shares of Incyte in a report on Tuesday, September 17th. Finally, BMO Capital Markets reaffirmed an "underperform" rating and issued a $52.00 price target (up previously from $48.00) on shares of Incyte in a report on Wednesday. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $76.74.

Incyte Company Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.